Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery

Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery - Treatment of postoperative nausea and vomiting (PONV) after prophylactic administration of ondansetron in oral surgery

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059821

Enrollment

Registered

2025-11-25

Start date

2025-11-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

jaw deformity

Interventions

In the ondansetron group, patients who develop PONV after prophylactic administration of ondansetron receive an additional 4 mg of ondansetron. If PONV does not improve, 10 mg of metoclopramide is adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing orthognathic surgery ASA-PS 1-2 Patient who gave consent for this study

Exclusion criteria

Exclusion criteria: <20 or >50 years of age, ASA-PS 3 or higher, patient who did not give consent for this study,use of antiemetics within 24 h before surgery, contraindicated for administration of medications used in this study, emergency surgery

Design outcomes

Primary

Measure	Time frame
Improvement rate of PONV 15 minutes after administration of therapeutic drugs(study drug I) for PONV occurring despite prophylactic ondansetron administration	—

Secondary

Measure	Time frame
Patient background (age, sex, height, weight, smoking history, and presence or absence of motion sickness/ PONV) surgical and anesthetic factors (operation name, operation time, anesthesia time, total infusion volume, blood loss, intraoperative opioid use, and postoperative opioid use) Improvement rate of PONV 15 minutes after administration of the investigational drug (Study Drug II) for PONV that occurred after administration of Study Drug I Degree of PONV (change in NRS 15 minutes after administration of study drug I and II, presence or absence of vomiting up to 24 hours after the end of anesthesia)	—

Measure

Time frame

Patient background (age, sex, height, weight, smoking history, and presence or absence of motion sickness/ PONV) surgical and anesthetic factors (operation name, operation time, anesthesia time, total infusion volume, blood loss, intraoperative opioid use, and postoperative opioid use) Improvement rate of PONV 15 minutes after administration of the investigational drug (Study Drug II) for PONV that occurred after administration of Study Drug I Degree of PONV (change in NRS 15 minutes after administration of study drug I and II, presence or absence of vomiting up to 24 hours after the end of anesthesia)

—

Countries

Japan

Contacts

Public Contacthidetoshi kanawa

Tokyo Dental College Dental Anesthesiology

kanawahidetoshi@tdc.ac.jp03-6380-9001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026